Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Retrieved on:
Tuesday, August 22, 2023
Research, FDA, Clinical Trials, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Science, Oncology, Lymphoma, CD47, Partnership, Drug development, Nature, Therapy, Crown Bioscience International, CDX, Raji, Innovation, Toxicity, Doctor of Philosophy, PDX, Organization, Collection, TME, Scientific Reports, Mouse, PD-1, Hanx!, IND, Tumor microenvironment, Palladium, Pharmaceutical industry, Medical imaging
In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China.
Key Points:
- In addition, HX009 exhibited enhanced T-cell activating capability over HX008, an approved and marketed anti-PD-1 monoclonal antibody in China.
- Additionally, custom patient-derived xenograft (PDX) models established by Crown Bioscience, further confirmed the efficacy of CD47 targeting by HX009.
- These Crown Bioscience studies played an important role in supporting the application of HX009 for the treatment of lymphoma in clinical trials.
- Henry Li, PhD, Cofounder, Chief Executive Officer and Chief Scientific Officer of HanX, stated: “We are delighted with the exceptional outcomes of our partnership with Crown Bioscience.